مباشر

Clinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected Future FierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EY FierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market BioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studies Endpoints NewsA different approach to lowering healthcare costs CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity Clinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics BioPharma DiveStealthy startup Treeline plans a reverse merger 10x Genomics Blog10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybiz Endpoints NewsHow K Health moved AI chatbots into hospitals 10x Genomics News10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - BioSpace BioWorldGSK grabs cancer firm Nuvalent for $10.6B in cash

FierceBiotech ٩ يونيو ٢٠٢٦

Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabi...

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has upsized its own IPO plans with the potential to eclipse that record.